Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UHRF1 | Q96T88 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.39 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.35 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.35 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.34 |
| ▸ | RECQL | P46063 | 2/20 | 0.33 |
| ▸ | IDH1 | O75874 | 2/20 | 0.33 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29505699 | 1.00 | UHRF1 (0.46) | UHRF1KDM4ES1PR2TSHRMEN1 | |
| Formaldehyde SCHEMBL28191892 | 0.94 | UHRF1 (0.42) | UHRF1KDM4ES1PR2TSHRMEN1 | |
| SCHEMBL21927208 | 0.84 | UHRF1 (0.38) | UHRF1KDM4ETSHRCYP1A2CYP2A6 | |
| SCHEMBL2751008 | 0.82 | UHRF1 (0.41) | UHRF1KDM4ETSHRMEN1KMT2A | |
| SCHEMBL21927619 | 0.80 | EGLN2 (0.41) | KDM4ES1PR2TSHRCSNK1A1CLK4 | |
| SCHEMBL3826142 | 0.78 | S1PR2 (0.37) | KDM4ES1PR2TSHRMEN1KMT2A | |
| SCHEMBL20642285 | 0.78 | S1PR2 (0.37) | KDM4ES1PR2TSHRKMT2ACSNK1A1 | |
| SCHEMBL11744305 | 0.78 | S1PR2 (0.40) | KDM4ES1PR2TSHRCSNK1A1CLK4 | |
| SCHEMBL31750396 | 0.78 | S1PR2 (0.46) | KDM4ES1PR2TSHRKMT2ACYP1A2 | |
| SCHEMBL14068317 | 0.78 | S1PR2 (0.37) | KDM4ES1PR2TSHRKMT2ACSNK1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 113 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115636781-A | Synthesis method of 2, 4-dimethyl-5-aminopyridine | 山西永津集团有限公司 | 2023-01-24 | — | — | CN | claimed |
| EP-3364967-B1 | FERROPORTIN INHIBITORS | VIFOR INT AG (CH) | 2026-05-20 | — | — | EP | disclosed |
| EP-3365339-B1 | NOVEL FERROPORTIN INHIBITORS | VIFOR INT AG (CH) | 2025-07-16 | — | — | EP | disclosed |
| WO-2025068710-A1 | COMPOUNDS COMPRISING AN IMIDAZOLE CORE | Tay Therapeutics Limited (GB) | 2025-04-03 | — | — | WO | disclosed |
| CN-116813621-A | 9H purine compounds, pharmaceutical composition and application thereof | 江南大学 | 2023-09-29 | — | — | CN | disclosed |
| US-20230234970-A1 | IMMUNOSUPPRESSANT, AND PREPARATION METHOD THEREFOR AND USE THEREOF | ABBISKO THERAPEUTICS CO., LTD. (CN) | 2023-07-27 | — | — | US | disclosed |
| CN-115636781-A | Synthesis method of 2, 4-dimethyl-5-aminopyridine | 山西永津集团有限公司 | 2023-01-24 | — | — | CN | disclosed |
| CN-115636781-A | Synthesis method of 2, 4-dimethyl-5-aminopyridine | 山西永津集团有限公司 | 2023-01-24 | — | — | CN | disclosed |
| WO-2022258023-A1 | COMPOUND AS CDK KINASE INHIBITOR AND USE THEREOF | 郑州同源康医药有限公司 | 2022-12-15 | — | — | WO | disclosed |
| US-20220363675-A1 | Novel Ferroportin Inhibitors | VIFOR (INTERNATIONAL) AG (CH) | 2022-11-17 | — | — | US | disclosed |
| WO-2003002556-A1 | NOVEL HETEROARYL DERIVATIVES, THEIR PREPARATION AND USE | H. LUNDBECK A/S (DK) | 2003-01-09 | — | — | WO | disclosed |
| EP-1231207-A1 | NOVEL BIPYRIDYL DERIVATIVES | Sankio Chemical Co., Ltd. (JP) | 2002-08-14 | — | — | EP | disclosed |
| US-5821255-A | REGULATING THE SECRETION OF CORTICOTROPIN, BETA-ENDORPHIN OR PEPTIDES DERIVED FROM PROOPIOMELANOCORTIN | SANOFI (FR) | 1998-10-13 | — | — | US | disclosed |
| EP-0659747-B1 | Branched aminothiazole derivatives process for their preparation and pharmaceutical compositions containing them | SANOFI SA (FR) | 1998-04-01 | — | — | EP | disclosed |
| US-5602132-A | USEFUL IN TREATMENT OF PATHOLOGIES INVOLVING CORTICOTROPIN RELEASING FACTOR | SANOFI (FR) | 1997-02-11 | — | — | US | disclosed |
| CN-1127252-A | Branched-amino-sbustituted thiazoles, processes for their preparation and the pharmaceutical compositions which contain them | SANOFI SA (FR) | 1996-07-24 | — | — | CN | disclosed |
| EP-0659747-A1 | Branched aminothiazole derivatives process for their preparation and pharmaceutical compositions containing them | SANOFI (FR) | 1995-06-28 | — | — | EP | disclosed |
| EP-0104876-B1 | HERBICIDAL CYCLOHEXANE-1,3-DIONE DERIVATIVES | ICI AUSTRALIA LIMITED (AU) | 1991-12-27 | — | — | EP | disclosed |
| US-4631081-A | Herbicidal cyclohexane-1,3-dione derivatives | ICI AUSTRALIA LIMITED (AU) | 1986-12-23 | — | — | US | disclosed |
| EP-0104876-A2 | Herbicidal cyclohexane-1,3-dione derivatives | ICI AUSTRALIA LIMITED (AU) | 1984-04-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230234970-A1 | IMMUNOSUPPRESSANT, AND PREPARATION METHOD THEREFOR AND USE THEREOF | CD274, PDCD1, PDCD1LG2 | UHRF1 1612/4885KDM4E 2535/4885S1PR2 2131/4885 |
| US-20220363675-A1 | Novel Ferroportin Inhibitors | HAMP, SLC40A1, HMOX1 | UHRF1 3811/4885KDM4E 4503/4885S1PR2 877/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.